Literature DB >> 9111993

A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis.

M Seri1, I Celli, N Betsos, F Claudiani, G Camera, G Romeo.   

Abstract

Germ-line mutations of the RET proto-oncogene, involving five cysteine residues at codons 609, 611, 618, 620 and 634, are associated with two variants of the inherited cancer syndrome multiple endocrine neoplasia type 2: type 2A and familial medullary thyroid carcinoma. The association of multiple endocrine neoplasia type 2A with the dermatological disorder cutaneous lichen amyloidosis has already been reported, and mutations in the Cys634 have been identified in different families. We describe here an additional pedigree in which multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis cosegregate. A Cys634Gly was identified by direct sequencing of the RET proto-oncogene exon 11 in the affected individuals. The mutation creates a new HaeIII site, and restriction analysis performed on all family members rules out the presence of the altered allele in two children and consequently the risk of developing thyroid tumors. These results emphasize the role of molecular analysis of the RET proto-oncogene in diagnosing presymptomatically those individuals at risk of inheriting the disease allele.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111993     DOI: 10.1111/j.1399-0004.1997.tb02425.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 2.  MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics.

Authors:  Jessica Oliboni Scapineli; Lucieli Ceolin; Márcia Khaled Puñales; José Miguel Dora; Ana Luiza Maia
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

3.  Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma.

Authors:  S Gullu; A Gursoy; M F Erdogan; S Dizbaysak; G Erdogan; N Kamel
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 4.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis.

Authors:  Ken Arita; Andrew P South; Günter Hans-Filho; Thais Harumi Sakuma; Joey Lai-Cheong; Suzanne Clements; Maçanori Odashiro; Danilo Nakao Odashiro; Günter Hans-Neto; Nelise Ritter Hans; Maxine V Holder; Balbir S Bhogal; Sian T Hartshorne; Masashi Akiyama; Hiroshi Shimizu; John A McGrath
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

6.  RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Authors:  Xiao-Ping Qi; Jian-Qiang Zhao; Zhen-Guang Chen; Jin-Lin Cao; Juan Du; Nai-Fang Liu; Feng Li; Mao Sheng; Er Fu; Jian Guo; Hong Jia; Yi-Ming Zhang; Ju-Ming Ma
Journal:  Oncotarget       Date:  2015-10-20

Review 7.  5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Authors:  Shu-Yuan Li; Yi-Qiang Ding; You-Liang Si; Mu-Jin Ye; Chen-Ming Xu; Xiao-Ping Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

Review 8.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

9.  The RET C611Y mutation causes MEN 2A and associated cutaneous

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Li Zao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.